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Solid-phase extractiona b s t r a c t
The study of low abundant proteins contributes to increasing our knowledge about (patho)physiological
processes and may lead to the identiﬁcation and clinical application of disease markers. However,
studying these proteins is challenging as high-abundant proteins complicate their analysis. Antibodies
are often used to enrich proteins from biological matrices prior to their analysis, though antibody-free
approaches have been described for some proteins as well. Here we report an antibody-free workﬂow
on the basis of strong cation exchange (SCX) enrichment and liquid chromatography-mass spectrometry
(LC-MS) for quantiﬁcation of the soluble Receptor of Advanced Glycation End-products (sRAGE), a
promising biomarker in chronic obstructive pulmonary disease (COPD). sRAGE was quantiﬁed in serum
at clinically relevant low to sub ng mL1 levels. The method was validated according to U.S. Food and
Drug Administration (FDA) and European Medicines Agency (EMA) guidelines and was compared to an
antibody-based LC-MS sRAGE method. The SCX-based method builds upon the bipolar charge distri-
bution of sRAGE, which has a highly basic N-terminal part and an acidic C-terminal part resulting in an
overall neutral isoelectric point (pI). The highly basic N-terminal part (pIcalculated¼ 10.3) allowed for
sRAGE to be enriched by SCX at pH 10, a pH at which most serum proteins do not bind. This study showsry disease; DDA, data-dependent acquisition; EMA, European Medicines Agency; FDA, Food and Drug Administration;
n exchange; SCX, strong cation exchange; SIL, stable-isotope-labeled; SNP, single nucleotide polymorphism; (s)RAGE,
s.
B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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proteins following a thorough analysis of their physical-chemical properties.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The quantiﬁcation of proteins in blood-based samples is one of
the hallmarks of modern laboratory medicine and allows for the
diagnosis and staging of disease as well as for monitoring disease
progression and treatment efﬁcacy. Blood is, however, a highly
complex matrix with only a few proteins (e.g. albumin, immuno-
globulins) accounting for most of the total protein content [1].
These high abundant proteins complicate the analysis of many
other proteins and often need to be depleted to enable the detec-
tion of clinically relevant proteins of lower abundance [2,3].
Antibody-based enrichment procedures are commonly used to
enrich low abundant proteins prior to their quantiﬁcation, yet it has
been shown in recent years that antibody-free workﬂows can
quantify proteins in the ng mL1 range as well [4]. Antibody-free
workﬂows are based on speciﬁc properties of a target protein
that allow it to be separated frommost other proteins in a biological
sample. For example, some small, hydrophobic proteins can be
enriched following protein precipitation procedures in which these
smaller proteins remain in solution while larger proteins denature
and precipitate [5]. In addition, proteins exhibiting regions rich in
histidine, cysteine, and/or tryptophan residues, which form com-
plexes with transition metal ions (e.g. Zn2þ, Cu2þ, Ni2þ, Co2þ), can
be enriched by immobilized metal afﬁnity chromatography (IMAC)
[6]. Solid-phase extraction (SPE) furthermore offers a range of op-
tions for efﬁcient enrichment of protein subclasses with speciﬁc
physical-chemical properties. For example, proteins with an
elevated net negative or positive charge can be enriched by strong
anion exchange (SAX) or strong cation exchange (SCX)-based pro-
cedures, respectively [4].
The soluble Receptor of Advanced Glycation End-products
(sRAGE) is an example of a clinically relevant protein of low
abundance, which can currently only be quantiﬁed using afﬁnity
ligands (e.g. antibodies). This protein is a circulating form of
membrane-bound RAGE, an important receptor of the innate im-
mune system that is involved in triggering and sustaining inﬂam-
mation, in particular in the lungs [7]. sRAGE is formed after
proteolytic cleavage of RAGE by metalloproteases (e.g. ADAM10,
MMP9) or by alternative splicing of the AGER gene leading to the so-
called endogenous secretory RAGE (esRAGE) splice variant. sRAGE
is proposed to act as a decoy receptor for various pro-inﬂammatory
RAGE ligands thereby attenuating inﬂammation [8e11]. Several
large-scale clinical studies advanced sRAGE as promising
biomarker for chronic obstructive pulmonary disease (COPD), and
sRAGE is currently being considered for biomarker qualiﬁcation by
the U.S. Food and Drug Administration (FDA) [12,13].
sRAGE is a member of the immunoglobulin superfamily and
consists of three immunoglobulin-like domains, the N-terminal ‘V
domain’, the ‘C1 domain’, and the C-terminal ‘C2 domain’, which
together result in a fairly neutral isoelectric point (pI) [7,8]. How-
ever, the V domain of sRAGE displays a net positive charge at
neutral pH due to 16 positively charged amino acids versus 7
negatively charged residues, whereas its C2 domain displays a net
negative charge at neutral pH by carrying 10 negatively charged
amino acids versus 3 positively charged residues (see Fig. A.1). The
bipolar charge distribution of sRAGE thereby provides opportu-
nities for ion exchange-based protein enrichment, which is notobvious when solely considering the average pI of this protein.
In this study, we developed an ion-exchange-based enrichment
approach for the quantiﬁcation of sRAGE in human serum by liquid
chromatography-mass spectrometry (LC-MS) at clinically relevant
low to sub ng mL1 levels. In addition, we identiﬁed other low
abundant proteins for which ion-exchange-based protein enrich-
ment may represent an alternative to the commonly-used afﬁnity-
based strategies for quantiﬁcation by LC-MS.2. Materials and methods
2.1. Chemicals and materials
Recombinant human sRAGE (rh-sRAGE; Cat. No. C423; Uni-
ProtKB ID ‘Q15109’; Ala23-Ala344 with C-terminal hexa-histidine
tag) was purchased from Novoprotein (Summit, NJ, U.S.A.) and
stable-isotope-labeled sRAGE peptides (SIL peptides; i.e. IGEPLVLK*
& VLSPQGGGPWDSVAR*) were synthesized by Pepscan Presto
(Lelystad, The Netherlands). TSKgel SP-3PW SCX resin (250 Å; Cat.
No. 0021977; this resin was used for all experiments described in
this manuscript unless stated otherwise), TSKgel SP-5PW SCX resin
(1000 Å; Cat. No. 0043282), and TSKgel SuperQ-5PW SAX resin
(1000 Å; Cat. No. 0043283) were supplied by Tosoh Bioscience
(Darmstadt, Germany) and empty solid-phase extraction reservoirs
(Cat. No. 120e1111-A) were purchased from Biotage (Uppsala,
Sweden). Acetonitrile (Cat. No. 01200702) was obtained from Bio-
solve (Valkenswaard, The Netherlands), ethanol (Cat. No.
1.00983.2500) from VWR (Amsterdam, The Netherlands), ammonia
(Cat. No. 1054321000) from Merck (Amsterdam, The Netherlands),
and sequencing grade modiﬁed trypsin (Cat. No. V5111) from
Promega (Madison, WI, U.S.A.). Acetic acid (Cat. No. 1000631000),
ammonium acetate (Cat. No. 73594), and all other chemicals were
purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands).2.2. Serum samples
Pooled human serum from Seralab (West Sussex, U.K.) was used
directly as QC-low sample or was fortiﬁed with rh-sRAGE at two
levels to obtain the QC-medium and QC-high samples. Recovery
and spike recovery experiments as well as shotgun proteomics
experiments were carried out using six different sources of human
serum from healthy subjects (all from Seralab).2.3. Calibrants and internal standard
rh-sRAGE was dissolved in Milli-Q water to obtain a
200 mgmL1 solution (based on the quantity as declared by the
supplier) which was diluted to 100 mgmL1 with 10mM phosphate
buffered saline, pH 7.4. The resulting solution was sequentially
diluted to 100 ngmL1 with rat serum, and calibration samples
were prepared at 0.2, 0.5, 1.0, 2.0, 5.0, 8.0 and 10.0 ngmL1 in rat
serum. The internal standard (IS) stock solution was prepared by
mixing equimolar amounts of the two SIL-peptides (supplied as
5 pmol mL1 solutions in 5% ACN) and subsequently diluting these
peptides to 5 fmol mL1 with 1% dimethyl sulfoxide (DMSO) in
water.
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The supplied suspension of the SCX resin was homogenized by
agitation and 100 mL of this suspension was transferred to a
microcentrifuge tube. The resin was washed with 800 mL ethanol
and then with 800 mL 20mM ammonium acetate, pH 10 (SCX
buffer) by gentle vortex-mixing after which the resin was pelleted
by centrifugation (3000 g; 2min), and the washing solution was
discarded. Next, the resin was resuspended in 750 mL SCX buffer
and 50 mL of serum (or calibrant) was added. After 15min of incu-
bation on a rotating wheel, the sample was brieﬂy centrifuged to
spin down droplets from the lid, and the resin was loaded into an
empty SPE reservoir which was placed in a Varian Cerex™ SPE
processor (positive pressure was applied to let solvents pass
through the SPE reservoirs in a dropwise manner) and which had
been rinsed with 1mL water. The resin was subsequently washed
with 1mL SCX buffer, and sRAGE was eluted with 250 mL of a 1%
aqueous ammonia solution and then collected in low binding tubes
(Eppendorf; Cat. No. 525e0133) containing 50 mL of a 15% aqueous
acetic acid solution. After drying the eluate in a vacuum centrifuge
at 60 C, the residue was reconstituted in 50 mL Digestion Buffer
(100 fmolmL1 SIL-peptides in 100mM ammonium bicarbonate
(ABC)). Next, disulﬁde bonds were reduced with 10mM dithio-
threitol (DTT; 5 mL 110mM DTT in ABC) for 30min (60 C; 600
RPM), and thiols were alkylated with 20mM iodoacetamide (IAM;
5 mL 240mM IAM in ABC) for 30min in the dark (room tempera-
ture). After quenching the excess of IAM with a 0.5M excess of DTT
(5.5 mL of 110mM DTT), 100 ng trypsin was added to each sample,
and proteins were digested overnight (37 C; 600 RPM). The digests
were acidiﬁed by adding 5 mL of 25% formic acid (FA), and 20 mL of
sample was analyzed by LC-MS in the multiple reaction monitoring
(MRM) mode.
2.5. Targeted analysis by LC-MRM/MS
Targeted analyses were performed on a Waters Ionkey/MS sys-
tem using an ACQUITY M-Class UPLC and a XEVO TQ-S mass
spectrometer (Milford, MA, U.S.A.). Chromatographic separation
was achieved on a C18-bonded Waters iKey HSS T3 Separation
Device (1.8 mmparticles,100 Å pore size,150 mm 100mm; Cat. No.
186007261) at 40 C using 0.1% FA in H2O as mobile phase A and
0.1% FA in ACN asmobile phase B. 20 mL of samplewas loaded onto a
Dionex Acclaim PepMap100C18 trap column (5 mm particles, 100 Å
pore size, 300 mm 5mm; Cat. No.160454) for 4.5minwith 3% B at
20 mLmin1. Peptides were subsequently separated on the analyt-
ical column at 3 mLmin1 with a 10min linear gradient from 3 to
33% B, after which the column was cleaned (0.6min at 60% B and
2.1min at 95% B) and equilibrated (4.3min at 3% B). Mass spectro-
metric detectionwas performed using the following conditions: ESI
positive, capillary voltage 3.5 kV, cone voltage 30 V, source offset
50 V, source temperature 120 C, cone gas (nitrogen) ﬂow 150 L h1,
sheath (nanoﬂow) gas (nitrogen) ﬂow 0.2 bar, and collision gas
(argon) ﬂow 0.15mLmin1. MRM transitions and settings for
IGEPLVLK (selected for quantiﬁcation) and VLSPQGGGPWDSVAR
(selected for conﬁrmation) are presented in Table A.1. The Ionkey/
MS systemwas operated under theWatersMassLynx software suite
(version 4.1), and the TargetLynx module of this package was used
for data processing.
2.6. Method validation and comparison
Themethod was validated according to EMA and FDA guidelines
by addressing the following criteria: selectivity (e.g. spike recov-
ery), accuracy & precision, recovery, calibration curve, and stability
(e.g. 6 days benchtop, 5 freeze-thaw, and 6 days autosampler(10 C)) [14,15]. Samples were fortiﬁedwith 5 ngmL1 sRAGE either
before or after SCX-SPE to obtain the pre-SCX-SPE spiked and post-
SCX-SPE spiked samples for recovery assessment, respectively. For
the spike-recovery experiments, samples were processed either
directly or were fortiﬁed with 5 ngmL1 sRAGE (before SCX-SPE) to
obtain the non-spiked and spiked samples, respectively. Further-
more, the method was compared with a previously developed
immunoafﬁnity-LC-MS method for sRAGE quantiﬁcation [16]. For
this purpose, 40 serum samples were analyzed from a cross-
sectional study (NCT00807469) within the University Medical
Center Groningen (UMCG) [17]. Ethical approval for this study had
been granted by the UMCG's review board (METc 2008/136), and
the study adheres to the Declaration of Helsinki. Blood samples
were collected as described previously [16].
2.7. Shotgun proteomics
Proteins enriched by SCX at pH 10 (see ‘SCX-Based sRAGE
Enrichment’ paragraph above) or SAX at pH 4 (SPE was performed
following the same steps as described in the ‘SCX-Based sRAGE
Enrichment’ paragraph above, however, with the following solu-
tions: loading and washing with 20mM ammonium acetate, pH 4;
elution with 250 mL 3% aqueous acetic acid; and eluate collection in
50 mL 5% aqueous ammonia) were identiﬁed on the basis of six
serum samples. For these experiments, TSKgel SuperQ-5PW SAX
and TSKgel SP-5PW SCX resins were used, and a trichloroacetic acid
(TCA) precipitation step was included after SPE-enrichment to
concentrate the samples. Brieﬂy, the SPE eluates were mixed 1:1
(v:v) with a 12% aqueous TCA solution, incubated for 5min at 60 C,
placed on ice for at least 30min, vortexed-mixed, and centrifuged
(10min; 20,000 g; 4 C). After discarding (most of) the superna-
tant, 400 mL ice-cold acetone was added, the samples were vortex-
mixed and centrifuged (5min; 20,000 g; 4 C), and (most of) the
supernatant was removed after which the pellets were left to dry in
air. Shotgun proteomics analyses were performed using an Ulti-
Mate 3000 RSLC UHPLC system connected to an Orbitrap Q Exactive
Plus mass spectrometer operating in the data-dependent acquisi-
tion (DDA) mode. A sample volume of 6 mL was injected onto an
Acclaim PepMap100C18 trap column (see above) using mL-pickup
with 0.1% FA in H2O at 20 mLmin1. Peptides were separated on an
Acclaim PepMap RSLC C18 analytical column (2 mm particles, 100 Å
pore size, 75 mm 500mm; Cat. No. 164540) at 40 C using a
60min linear gradient from 3 to 50% eluent B (0.1% FA in ACN) in
eluent A (0.1% FA in H2O) at a ﬂow rate of 200 nLmin1. For DDA,
survey scans from 300 to 1650m/z were acquired at a resolution of
70,000 (at 200m/z) with an AGC target value of 3 106 and a
maximum ion injection time of 50ms. From the survey scan, a
maximum number of 10 of the most abundant precursor ions with
a charge state of 2þ to 6þwere selected for fragmentation by higher
energy collisional dissociation (HCD). Fragment ion spectra were
acquired between 200 and 2000m/z at a resolution of 17,500 (at
200m/z) with an AGC target value of 1 105, a maximum ion in-
jection time of 110ms, a normalized collision energy of 28%, an
isolation window of 1.6m/z, an intensity threshold of 1 104, and
the dynamic exclusion parameter set at 15 s. Shotgun proteomics
data were processed using PEAKS Studio software (version 8.5)
[18], and peak lists were searched against the UniProtKB homo sa-
piens ‘UP000005640’ reference proteome (canonical; 40,424 en-
tries; downloaded on August 22, 2017) with trypsin selected as
protease (3 missed cleavages), cysteine carbamidomethylation as
ﬁxed modiﬁcation, methionine oxidation as variable modiﬁcation,
and allowing 6 modiﬁcations per peptide, 10.0 ppm precursor
mass deviation (using monoisotopic mass), 0.2 Da fragment ion
mass deviation, and 0.1% false discovery rates (FDR) for peptide-
spectrum matches (PSMs), peptides and proteins, as well as
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3. Results and discussion
3.1. SCX-based protein enrichment
The bipolar charge distribution of sRAGE, which has an average
pI of 7.8 (calculated using Expasy's ProtParam tool [19] for the
extracellular domain of RAGE, Ala23-Ala342), formed the basis for
protein enrichment based on ion-exchange solid-phase extraction.
On the one hand, the C-terminal C2 domain of sRAGE with a pI of
4.6 (Pro227-Ser317) allowed for binding to the SAX material down
to pH 6 (see Fig.1a), while the N-terminal V domainwith a pI of 10.3
(Ala23-Arg116) bound to the SCX material up to pH 10 (see Fig. 1b).
The latter strategy was selected for quantitative method develop-
ment given that most human proteins are acidic in nature [20].
The SCX-based protein enrichment method was developed us-
ing highly cross-linked polymethacrylate beads functionalized with
sulfopropyl groups. Resin was transferred into an empty SPE car-
tridge after incubation with serum under alkaline conditions (pH
10). Loading and washing were performed using a 20mM ammo-
nium acetate buffer, pH 10 (see Fig. A.2), sRAGE was eluted from the
SCXmaterial with 1% aqueous ammonia (pH appr. 11.5), and eluates
were directly neutralized by collecting them in tubes containing
15% aqueous acetic acid (see Fig. A.3). The eluate was subsequently
dried to reduce the sample volume and to remove most of the
ammonium acetate. Including a TCA precipitation step after SCX
enrichment instead of drying the eluates was also tested and
resulted in a faster protocol and cleaner samples. However, the
corresponding protein pellets were fragile and detached easily from
the walls of the tubes leading to outliers that were incompatible
with a validated quantitative bioanalytical method. The TCA pre-
cipitation procedure was, however, used for the shotgun proteomic
analyses (see protocol outlined in the ‘Shotgun proteomics’ para-
graph of the experimental section and corresponding data in the
‘Ion exchange-based protein enrichment for targeted protein bio-
analysis by LC-MS’ paragraph below).
3.2. Quantitative assay development
sRAGE was detected by means of two unique tryptic peptides.
r.IGEPLVLK.c (30e37) was selected as quantiﬁer peptide, since thisFig. 1. Enrichment of endogenous sRAGE from serum by (a) strong anion exchange
(SAX) and (b) strong cation exchange (SCX) solid-phase extraction (SPE) at different pH
values. In these experiments, TSKgel SuperQ-5PW SAX and TSKgel SP-5PW SCX resins
were used and SPE conditioning, loading, and washing steps were performed as
described in the ‘Shotgun proteomics’ paragraph of the experimental section. Next,
sRAGE was eluted with 1M NaCl and 0.02% Tween-20 in 10mM phosphate buffer, pH
7.2, which allowed the eluates to be directly processed with a previously developed
sRAGE immunoafﬁnity enrichment procedure [16] in order to reduce sample
complexity (mostly relevant for the pH 6e8 samples) which was required for mass
spectrometric detection of endogenous sRAGE.peptide performed best in terms of accuracy and precision.
k.VLSPQGGGPWDSVAR.v (63e77) was selected as qualiﬁer peptide
due to its deamidation-prone ‘QG’ sequence motif and due to a
single nucleotide polymorphism (SNP) leading to an arginine-to-
cysteine substitution (i.e. rs116828224) with an expected fre-
quency of 0.6% in the general population (based on data from the
ExAC Browser [21]). Both peptides are derived from the V domain
and thereby reﬂect the fraction of sRAGE forms (so-called ‘pro-
teoforms’ or ‘protein species’) [22,23] to which most ligands will
bind [7,8]. Tryptic peptides from the C2-domain could not be
analyzed in parallel, as this domain only gives rise to two tryptic
peptides consisting of 41 and 43 amino acids, respectively, as well
as a C-terminal peptide containing an unknown proteolytic cleav-
age site as a result of RAGE shedding. The amino acid sequence of
the C1-domain should yield detectable tryptic peptides (with an
approximate maximal length of 20 amino acids), yet these peptides
were not detected in clinical samples possibly due to incomplete
digestion, low ionization efﬁciency, and/or loss of peptides during
sample preparation or LC-MS analysis.
3.3. Method validation
Table 1 summarizes the validation results. A full overview of all
validation results is given in Tables A.2 to A.10. Stable-isotope-
labeled (SIL) peptides were added after the SCX enrichment pro-
cedure, since a SIL version of sRAGE was not available. Variability
originating from the enrichment procedure could thus not be
compensated for, and sRAGE recovery after SCX enrichment was
accordingly evaluated during method validation. Recovery was
found to be 74% (see Table A.2) with a CV of 4% showing that sRAGE
enrichment by SCX was reproducible according to the FDA guide-
lines for bioanalytical method validation. The recovery of a previ-
ously developed antibody-based enrichment procedure was 83%
with a CV of 4% thereby being somewhat higher but equally
reproducible [16].
For preparing the calibration curve, we found that a surrogate
matrix of sufﬁcient complexity (e.g. serum from other organisms)
was required and that a simple, artiﬁcial matrix consisting of
bovine serum albumin (BSA) in PBS gave very low sRAGE recovery.
We reasoned that BSA will be depleted following SCX at pH 10, as
this protein has a calculated pI of 5.6, and that the sample after SCX-
SPE will have a very low remaining protein concentration thereby
likely inducing adsorption of sRAGE after the enrichment proced-
ure. Complex matrices, in turn, are expected to lead to co-
enrichment of other proteins, which serve as carrier proteins pre-
venting sRAGE adsorption. Rat serum was found to be a suitable
surrogate matrix, as demonstrated by an average spike-recovery
bias of 10% (see Table A.3), which is well within acceptable limits
(±15%).
Accurate quantiﬁcation of sRAGE at clinically relevant levels
between 0.2 and 10 ngmL1 was demonstrated for a 1/x weighted
linear calibration model using 7 non-zero standards. Reaching the
desired sensitivity was, however, challenging and considerable
chemical background was observed in the chromatograms of the
calibrants (see Fig. A.4a), though acceptable biases and CVs within
10%were found for all calibrants (see Table A.4). In comparisonwith
an immunoafﬁnity-LC-MS method for sRAGE quantiﬁcation [16],
chemical background was somewhat higher for samples that were
prepared using the SCX-SPE method, as became apparent from
selected ion chromatograms of six serum samples prepared with
both methods (see Fig. A.5a and A.5b). TCA precipitation after SCX
enrichment reduced the chemical background (see Fig. A.5c)
illustrating the added beneﬁt of incorporating such a step in the
protocol, provided that this procedure can be performed in a
reproducible manner without producing outliers.
Table 1
Summary of validation dataa.
QC-low QC-medium QC-high
CV biasb CV biasb CV biasb
accuracy & precision (3 runs, in 6-fold) run 1 14% 0% 7% 1% 12% 3%
run 2 15% 7% 14% 5% 10% 5%
run 3 5% 7% 14% 6% 13% 2%
autosampler stability 10 C (6 days, in 3-fold) 9% 3% 11% 3%
bench-top stability room temperature (6 days, in 3-fold) 14% 8% 1% 6%
freeze-thaw stability 20 C (5 cycles, in 3-fold) 2% 12% 10% 12%
Recovery CV bias
recovery (6 different serum samples) 74% 4%
spike recovery (6 different serum samples) 110% 9% 10%
a An extensive summary of the validation results is presented in Tables A.2 to A.10.
b The average value of measured concentrations during the precision and accuracy experiments was used as nominal concentration.
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to 7% for the three QC-samples, and precision was acceptable with
CVs below or equal to 15% (see Tables A.5 to A.7). Stability assess-
ments indicated that storing samples for 6 days on the benchtop or
subjecting them to 5 freeze-thaw cycles did not affect sRAGE levels
(see Tables A.8 and A.9). Stability of the ﬁnal peptide digests was
furthermore assessed for up to 6 days of storage in the autosampler
at 10 C and corresponding biases and CVs were well within the
acceptance limits (see Table A.10).
3.4. Method comparison
Agreement between the SCX-based LC-MS sRAGE method and a
previously developed antibody-based LC-MS sRAGE method [16]
was assessed on the basis of 40 clinical samples using linear
regression and Bland-Altman plots (see Fig. 2). Comparison be-
tween the two methods revealed moderate correlation (R2¼ 0.48)
and an increasingly positive bias for the SCX-based method with
increasing sRAGE concentrations relative to the antibody-based
method. Different sRAGE levels have been reported before when
comparing the antibody-based LC-MS method with a commercial
ELISA (i.e. the Human RAGE Quantikine ELISA kit from R&D Sys-
tems), which represents the most frequently used sRAGE assay in
clinical biomarker studies [16]. The ELISA was found to report 84%
lower sRAGE levels compared to the antibody-based LC-MS
method, while correlation between these assays was rather goodFig. 2. Comparison between the SCX-based LC-MS method (SCX) and a previously develop
Bland-Altman plots.with an R2 of 0.79.
These differences indicate that the measured sRAGE concen-
tration strongly depends on methodology even though all three
methods represent validated assays. It is, for example, conceivable
that the methods capture a different subset of sRAGE proteoforms
or sRAGE-containing complexes. sRAGE molecules are known to
bind to each other as well as to several other proteins [7], and the
binding sites of antibodies may thereby become inaccessible. In
addition, some proteoforms lack certain regions or feature speciﬁc
posttranslational modiﬁcations which might interfere with an
enrichment strategy. With respect to the ELISA and the antibody-
based LC-MS method, a lack of binding capacity of the antibodies
may furthermore be a reason for the lower levels reported by
these assays. In fact, an insufﬁcient binding capacity would affect
higher protein levels disproportionally, in agreement with the
increasingly positive bias for the SCX-based method shown in
Fig. 2. However, it should be noted that the antibody-based LC-MS
method was validated over a much wider concentration range
than strictly needed for the 40 samples included in the method
comparison. The increasingly positive bias of the SCX-based
method relative to the immunoafﬁnity-based method might also
be due to a lower afﬁnity of sRAGE for the SCX material, which
would affect lower concentrations to a greater extend. The linear
response of rh-sRAGE spiked in rat serum for the calibration
samples did, however, not indicate such an effect. A further caveat
is that data based on rh-sRAGE may not be representative fored antibody-based LC-MS method (Antibody) [16] using (a) linear regression and (b)
F. Klont et al. / Analytica Chimica Acta 1043 (2018) 45e5150endogenous sRAGE pointing to a general problem in biomarker
research, namely the lack of well-characterized authentic protein
standards.3.5. Ion exchange-based protein enrichment for targeted protein
bioanalysis by LC-MS
Unlike afﬁnity ligands which enrich their targets from a bio-
logical matrix based on well-deﬁned binding sites, ion exchange-
based enrichment procedures yield a series of proteins with com-
mon physical-chemical properties with respect to number of
charges and charge distribution under a given set of experimental
conditions. Several other proteins are therefore expected to be co-
enriched by the SCX-based method, and we aimed to identify more
proteins by shotgun proteomics in the SCX eluate at pH 10. We
extended these experiments to the enrichment of serum proteins
on an SAX resin at pH 4 to investigate whether the principle holds
for both types of ion exchangers. As expected, SCX-based enrich-
ment led to considerably less complex samples compared to SAX, as
reﬂected by 3 times higher total ion current and base peak chro-
matograms and twice as many identiﬁed proteins in the SAX-
enriched samples.
Table A.11 gives an overview of proteins that were identiﬁed in
the SCX- or SAX-enriched fractions of six different serum samples
after removing the top 20 high abundant blood proteins [3] and
common contaminants such as keratins from the results. Many of
the identiﬁed proteins were medium to high abundant blood pro-
teins such as apolipoproteins, coagulation-related proteins or pro-
teins of the complement system, yet some clinically relevant, lower
abundant proteins were identiﬁed as well. When viewing these
results, it must be kept in mind that MRM-based targeted protein
analyses are more sensitive than shotgun analyses due to the sto-
chastic nature of DDA. It is thus not surprising that sRAGE, the
protein biomarker that we quantiﬁed in the SCX fraction, was not
identiﬁed in any of the shotgun analyses.
Fig. 3 shows the calculated pI values of the proteins included in
Table A.11 plotted against their concentrations in the circulation, as
retrieved from the Plasma Proteome Database [24]. Based on the
scatter observed in both plots we concluded that the (calculated)
average pI is rather uninformative when aiming to predict the ion
exchange behavior of proteins. The SCX fraction, for example,
contained the low mg mL1 insulin-like growth factor binding
protein (IGFBP)3 (UniProtKB ID ‘P17936’) and the ng mL1 IGFBP5
(‘P24593’) and IGFBP7 (‘Q16270’), which all have an average pIFig. 3. Scatterplot displaying the relation between expected concentrations in blood
(based on data from the Plasma Proteome Database [24], accessed in April 2018) and
isoelectric points (pI; calculated for complete protein sequences using ExPASy's online
ProtParam tool [19]) of serum proteins enriched by (a) strong anion exchange (SAX)
solid-phase extraction at pH 4 and (b) strong cation exchange (SCX) solid-phase
extraction at pH 10 using TSKgel SuperQ-5PW SAX resin and TSKgel SP-5PW SCX
resin, respectively.between 8 and 9. In addition, A disintegrin and metalloprotease
with thrombospondin motifs 13 (ADAMTS13; ‘Q76LX8’) and inter-
cellular adhesion molecule 2 (ICAM2; ‘P13598’) were identiﬁed in
the SAX fraction and hepatocyte growth factor activator (HGFA;
‘Q04756’) was identiﬁed in both the SAX and SCX fractions, in spite
of their calculated average pIs of 7.0, 7.1, and 7.0, respectively. These
proteins likely contain charged domains, such as the 4 kDa short
chain of HGFA featuring a pI of 11.7 which might explain its binding
to the SCX resin at pH 10. These results thus open up new oppor-
tunities for enriching proteins by SAX at acidic or by SCX at basic
pH. Still, it is important to assess the charge distribution in a protein
rather than its calculated average pI when evaluating whether ion
exchange SPE might be suitable approach for enrichment. With any
prediction it must, however, be realized that post-translational
modiﬁcations may alter binding to ion exchangers thereby stress-
ing the signiﬁcance of a thorough analysis of the physical-chemical
properties of endogenous proteins. Furthermore, it should be taken
into account that conditions under which SAX and SCX are per-
formed can affect protein structure or stability. Protein stability
should therefore be evaluated and monitored closely when devel-
oping quantitative methods for intact proteins, whereas proteo-
typic peptide selection and evaluation should be done diligently
when developing quantitative methods targeting proteotypic
peptides.4. Conclusions
Protein enrichment is a prerequisite for many biological,
biomedical, and clinical studies. The availability of good quality
antibodies and other afﬁnity ligands have opened up and expanded
opportunities to study proteins for researchers working in biolog-
ical and medical sciences. Methods that do not rely on afﬁnity li-
gands are, however, also suitable to enrich proteins from complex
biological matrices with protocols that are as simple and straight-
forward as those of afﬁnity-based methods. These methods take
the speciﬁc physical-chemical characteristics of a protein of interest
into account, such as the presence of transition metal-chelating
sites, which can be targeted through immobilized metal afﬁnity
chromatography, or the presence of positively or negatively
charged regions, which can be targeted by ion exchange resins. The
resulting protocols enable the highly reproducible enrichment of
low abundant proteins from serum, as demonstrated by the
development and validation of a quantitative LC-MS method for
sRAGE based on a strong cation exchange enrichment procedure.
Our work furthermore emphasizes that protein concentrations
must be seen in the context of the methodology that was used to
measure them due to the complexity of the proteome and, as a
consequence, the possibility that different methods may enrich a
different subset of proteoforms. We showed further that ion
exchange-based enrichment represents a relevant option for
enriching other proteins of interest. However, for a rationally
designed ion exchange-based enrichment procedure it is essential
not to rely on the average, calculated isoelectric point of a protein
but to study its charge distribution along the three-dimensional
orientation of the molecule.Acknowledgments
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